In osteosarcoma, benign bone tumors, and bone metastases from primary tumors of different origin, SLCO1A2 mRNA expression levels were variable, making OATP1A2 a rather weak prognostic marker in these tumor entities [76]. This evidence concerns the gene SLCO1A2 and bone benign neoplasm.